DE69332540D1 - Rapamycinderivate - Google Patents

Rapamycinderivate

Info

Publication number
DE69332540D1
DE69332540D1 DE69332540T DE69332540T DE69332540D1 DE 69332540 D1 DE69332540 D1 DE 69332540D1 DE 69332540 T DE69332540 T DE 69332540T DE 69332540 T DE69332540 T DE 69332540T DE 69332540 D1 DE69332540 D1 DE 69332540D1
Authority
DE
Germany
Prior art keywords
rapamycin derivatives
rapamycin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332540T
Other languages
English (en)
Other versions
DE69332540T2 (de
Inventor
Juan Ignacio Luengo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
SmithKline Beecham Corp
Original Assignee
GlaxoSmithKline LLC
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC, SmithKline Beecham Corp filed Critical GlaxoSmithKline LLC
Publication of DE69332540D1 publication Critical patent/DE69332540D1/de
Application granted granted Critical
Publication of DE69332540T2 publication Critical patent/DE69332540T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69332540T 1992-07-17 1993-07-16 Rapamycinderivate Expired - Fee Related DE69332540T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91514692A 1992-07-17 1992-07-17
PCT/US1993/006678 WO1994002136A1 (en) 1992-07-17 1993-07-16 Rapamycin derivatives

Publications (2)

Publication Number Publication Date
DE69332540D1 true DE69332540D1 (de) 2003-01-16
DE69332540T2 DE69332540T2 (de) 2003-07-10

Family

ID=25435298

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332540T Expired - Fee Related DE69332540T2 (de) 1992-07-17 1993-07-16 Rapamycinderivate

Country Status (9)

Country Link
US (1) US5728710A (de)
EP (1) EP0650356B1 (de)
JP (1) JPH07509246A (de)
CN (1) CN1087913A (de)
AU (1) AU4679993A (de)
DE (1) DE69332540T2 (de)
MX (1) MX9304359A (de)
WO (1) WO1994002136A1 (de)
ZA (1) ZA935112B (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
SK78196A3 (en) * 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
EP0937082A2 (de) * 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Nicht immunhemmende antifungale rapaloge
CA2266039A1 (en) * 1996-09-09 1998-03-12 Thomas Joseph Caggiano Alkylated rapamycin derivatives
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
DE60315723T2 (de) 2002-07-16 2008-06-19 Biotica Technology Ltd. Herstellung von Polyketiden und anderen natürlichen Produkten
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
CN101084227B (zh) 2004-12-20 2011-11-16 惠氏公司 雷帕霉素类似物及其治疗神经紊乱、增殖性和炎性疾病的用途
CN101084226A (zh) 2004-12-20 2007-12-05 惠氏公司 雷帕霉素衍生物及其治疗神经紊乱的用途
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
RU2443418C2 (ru) 2005-07-20 2012-02-27 Новартис Аг КОМБИНАЦИЯ ПИРИМИДИЛАМИНОБЕНЗАМИДА И ИНГИБИТОРА КИНАЗ mTOR
KR20080071600A (ko) 2005-11-21 2008-08-04 노파르티스 아게 Ｍｔｏｒ 억제제를 사용하는 신경내분비 종양 치료법
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
EP2431036B1 (de) 2006-09-13 2017-04-12 Elixir Medical Corporation Makrocyclische Lactonverbindungen und Verfahren zu deren Verwendung
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CA2711765A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
JP2011525890A (ja) * 2008-03-11 2011-09-29 エリクサー・メディカル・コーポレイション 大環状ラクトン化合物およびそれらの使用方法
CN105380947A (zh) * 2008-03-11 2016-03-09 万能医药公司 大环内酯化合物及它们的使用方法
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
EP2470179B1 (de) 2009-08-26 2017-11-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Retard-freisetzungssysteme für die prävention und behandlung von kopf- und halstumoren
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
SG184311A1 (en) 2010-04-16 2012-11-29 Novartis Ag Combination of organic compounds
JP6170840B2 (ja) 2011-03-11 2017-07-26 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 抗ｃｄ４０抗体及びその使用
NZ615593A (en) 2011-04-25 2015-05-29 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
CN104519907A (zh) 2012-03-23 2015-04-15 昆士兰大学 免疫调节剂及其用途
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
EP2869818A1 (de) 2012-07-06 2015-05-13 Novartis AG Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
CA2905247C (en) 2013-03-13 2021-02-16 Santen Pharmaceutical Co., Ltd. Therapeutic agent for meibomian gland dysfunction
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
WO2014184734A1 (en) 2013-05-14 2014-11-20 Novartis Ag Markers associated with mtor inhibition
CN105283553B (zh) 2013-06-11 2021-06-25 克隆技术实验室有限公司 蛋白质富集的微泡及其制备和使用方法
RU2016104643A (ru) 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
WO2015044854A1 (en) 2013-09-24 2015-04-02 Novartis Ag Markers associated with mtor inhibition
AU2015216590A1 (en) 2014-02-11 2016-06-30 Novartis Ag Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
CN107073066B (zh) 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
ES2887602T3 (es) 2015-09-04 2021-12-23 Primatope Therapeutics Inc Anticuerpos anti-CD40 humanizados y usos de los mismos
CA3048217A1 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3053108A1 (en) 2017-02-10 2018-08-16 Mount Tam Therapeutics, Inc. Rapamycin analog
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
IL293443A (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
WO2019212990A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
JP7266043B2 (ja) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
JP7361720B2 (ja) 2018-05-10 2023-10-16 アムジエン・インコーポレーテツド がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
JP7357644B2 (ja) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA55136A (fr) 2018-11-19 2022-02-23 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
AU2019403488A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
WO2020132649A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MX2021008777A (es) * 2019-01-22 2022-01-06 Aeovian Pharmaceuticals Inc Moduladores de mtorc y usos de los mismos.
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3931195A1 (de) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclische heteroarylverbindungen und verwendungen davon
EP3738593A1 (de) 2019-05-14 2020-11-18 Amgen, Inc Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
CN114144414A (zh) 2019-05-21 2022-03-04 美国安进公司 固态形式
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
AU2020326627A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
AU2020325115A1 (en) 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
EP4007753A1 (de) 2019-08-02 2022-06-08 Amgen Inc. Kif18a-inhibitoren
EP4031542A4 (de) 2019-09-18 2023-10-25 Merck Sharp & Dohme LLC Kleinmolekülige inhibitoren der kras-g12c-mutante
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
KR20220106980A (ko) 2019-10-28 2022-08-01 머크 샤프 앤드 돔 코포레이션 Kras g12c 돌연변이체의 소분자 억제제
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4055028A1 (de) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras-inhibitoren
CN115873020A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
KR20220109408A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
TW202132271A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
EP4065231A1 (de) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Kovalente ras-inhibitoren und verwendungen davon
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4069223A4 (de) * 2019-12-05 2023-12-20 Janssen Pharmaceutica NV Rapamycinanaloga und verwendungen davon
BR112022010086A2 (pt) 2020-01-07 2022-09-06 Revolution Medicines Inc Dosagem do inibidor de shp2 e métodos de tratamento de câncer
MX2022011964A (es) 2020-03-27 2022-12-02 Aeovian Pharmaceuticals Inc Moduladores de mtorc1 y usos de los mismos.
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
EP4183395A1 (de) 2020-07-15 2023-05-24 Taiho Pharmaceutical Co., Ltd. Pyrimidinverbindung enthaltende kombination zur verwendung bei der tumorbehandlung
JP2023541236A (ja) 2020-09-03 2023-09-29 レボリューション メディシンズ インコーポレイテッド Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
EP4334325A1 (de) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras-hemmer zur behandlung von krebs
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4347041A1 (de) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Kleinmolekülige inhibitoren von kras-mutierten proteinen
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (de) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazinverbindungen als shp2-inhibitoren
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin

Also Published As

Publication number Publication date
US5728710A (en) 1998-03-17
EP0650356B1 (de) 2002-12-04
MX9304359A (es) 1994-04-29
CN1087913A (zh) 1994-06-15
WO1994002136A1 (en) 1994-02-03
ZA935112B (en) 1994-02-08
JPH07509246A (ja) 1995-10-12
AU4679993A (en) 1994-02-14
EP0650356A1 (de) 1995-05-03
EP0650356A4 (de) 1995-06-14
DE69332540T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
DE69332540D1 (de) Rapamycinderivate
DE69332484T2 (de) Rapamycinderivate
ATA75293A (de) Indolderivate
FI921328A (fi) Silyletrar av rapamycin
DK0833828T3 (da) Rapamycinderivater
FI931203A0 (fi) Karboxylsyraestrar av rapamycin
NO953406D0 (no) Pyrrolo-pyridinderivater
DE69332582D1 (de) Rapamycinderivate
DE69330497T2 (de) Chinazolin-derivate
DE59308714D1 (de) Cyclobutan-benzol-derivate
FI955164A0 (fi) Heterosykliset johdannaiset
DE69314072D1 (de) Cephalosporin-Derivat
FI950486A (fi) Amidijohdannaiset
NO952288D0 (no) Benzazepinon-derivater
DE69313890D1 (de) 5-Aminoflavon-Derivate
MX9206710A (es) Derivados de piridinol
DE59407726D1 (de) 3-Aryl-4-hydroxy-3-dihydrofuranon-Derivate
BR9104543A (pt) Derivados de triazolpiridazina
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
LV10955A (lv) Benzopirana atvasinajumi
DE69301681T2 (de) Oximderivate
NO932638D0 (no) 21-klor-pregnanderivat
DE59309038D1 (de) Chlorthiazolderivate
DE69400388T2 (de) Cyclohexendiolderivate
BR9306706A (pt) Derivados do triazolil-butano

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee